Enhanced Investments - Financial Portal

Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting

Published: 2021-09-03 11:05:00 ET

- Sam Tsimikas, M.D., senior vice president of clinical development, to moderate symposium on ATTR-CM

- CARDIO-TTRansform, a Phase 3 study of eplontersen for the treatment of ATTR-CM, will be featured on the Patients Association Channel

- Multiple presentations highlight new data and research into transthyretin amyloidosis

CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highlighting new scientific insights from its ATTR amyloidosis portfolio at the 3rd European ATTR Amyloidosis (EU-ATTR) meeting for Patients and Doctors on September 6-8, 2021. The posters and symposiums will include several presentations about Ionis' ATTR medicines, including its investigational antisense medicine, eplontersen, which is currently being evaluated in two phase 3 trials to potentially treat transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN). The presentations underscore Ionis' commitment to the ATTR amyloidosis community and the company's important work toward advancing treatment options for people impacted by the disease.

The following is a schedule of Ionis' events and activities to be held virtually at EU-ATTR:

Tuesday, Sept. 7 at 2:00 p.m. – 2:15 p.m. CESTPresentation: Gustavo Buchele, M.D., Ph.D., executive director, clinical development at Ionis, will present study design and trial details for CARDIO-TTRansform, which is currently enrolling, on the Patients Association Channel.
Wednesday, Sept. 8 at 2:00 p.m. – 2:45 p.m. CESTSatellite Symposium: Sotirios "Sam" Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader at Ionis, is moderating a satellite symposium about ATTR-CM and investigational antisense medicine, eplontersen, for Ionis' CARDIO-TTRansform Study, on the Doctors Channel. He will be joined by renowned cardiologists, Marianna Fontana, M.D., Ph.D., and Ahmad Masri, M.D., M.S. The event will discuss the landscape and future of ATTR-CM treatment and how Ionis aims to potentially change the standards of care with its novel LICA technology.

The following posters will be available to congress attendees at the start of the meeting:

Evaluation of the Efficacy and Safety of Eplontersen in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy: The CARDIO-TTRansform Study
Caregiving Burden Among Caregivers of Patients with ATTR Amyloidosis
Comparison of Symptoms Experienced by Patients with ATTRwt and hATTR: Findings from the Development of an ATTR-Specific Patient Reported Outcomes
Patient-Reported Outcomes by Time from Symptom Onset to First Pharmacotherapy Among Transthyretin Amyloidosis Patients
Clinical Characteristics of Patients with Mutations Associated with Hereditary Transthyretin Amyloidosis Versus Those Associated with Other Inherited Cardiovascular Diseases: Insights from a Genetic Testing Programme
Comparison of Patients with Mutations Associated with Hereditary Transthyretin Amyloidosis Versus Those Associated with Other Neuromuscular Diseases
Three Newly Recognized Likely Pathogenic Variants of The TTR Gene Causing Hereditary Transthyretin Amyloidosis
Cardiovascular Symptom Burden Prior to Diagnosis of Transthyretin Amyloid Cardiomyopathy Among Medicare Beneficiaries
The Patient Journey Prior to Diagnosis of Hereditary Transthyretin Amyloidosis
Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 3-Year Update
Inotersen on Neuropathy Symptom and Change Scores in Hereditary Transthyretin Amyloidosis: Subgroups and Responder Analyses
Efficacy of Inotersen for Neuropathic Impairment Scores in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Responder Analyses Examining the Impact of Inotersen on Neuropathic Impairment Score in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Treatment Satisfaction for Gene Silencing Pharmacotherapies in Hereditary Transthyretin Amyloidosis with Polyneuropathy

Details on presentation times can be found on the program website.

About Ionis Pharmaceuticals, Inc.

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.

To learn more about Ionis, visit www.ionispharma.com and follow us on twitter @ionispharma.

Ionis' Forward-looking Statement

This press release includes forward-looking statements regarding Ionis' business, and the therapeutic and commercial potential of Ionis' technologies and products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.

Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2020, and the most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available from the Company.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-host-attr-symposium-highlighting-cardio-ttransform-study-at-3rd-european-attr-amyloidosis-meeting-301368874.html

SOURCE Ionis Pharmaceuticals, Inc.

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.